Regeneron Pharmaceuticals (REGN) is witnessing dynamic changes in market sentiment. Notable firm Generate Investment Management Ltd liquidated its REGN shares, while Mirae Asset Global Investments Co. Ltd. and Sumitomo Mitsui DS Asset Management Company Ltd increased their holdings. The company's
Q4 2024 earnings revealed
strong revenue growth, with sales and earnings topping estimates. REGN also initiated a quarterly dividend and an additional stock buyback program, demonstrating strong financial health. Its new
EYLEA formula produced impressive results, halving eye injection frequency while maintaining performance, and Libtayo's success also added to the positive sentiment. Despite this, share prices reached a new one-year low. Analysts have conducted new price target evaluations, ranging from $759 to $1030, but these reductions and fluctuations could be contributing to investor uncertainty. REGN also faces a securities class action lawsuit, providing potential opportunities for shareholders who have experienced losses. Simultaneously, Leerink Partners upgraded the rating for REGN to a strong-buy. The company's
long-term investment analysis looks promising, with a 107% gain for investors over the past five years.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 21 Jan 2025 08:00:00 GMT to Sat, 08 Feb 2025 22:40:00 GMT -
Rating 0
- Innovation 7
- Information 8
- Rumor 3
